Guangzhou Innogen Pharmaceutl Grp Co EBIT

The latest EBIT for 2591.HK is $-550M as of June 2026. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Guangzhou Innogen Pharmaceutl Grp Co's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, 2591.HK currently prints $-550M for EBIT, while the sector average sits near $130B. That is roughly 100.4% below the sector mean. Large gaps often invite a closer look at Guangzhou Innogen Pharmaceutl Grp Co's growth, margins, and balance sheet.

A EBIT figure of $-550M for 2591.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting 2591.HK's EBIT ($-550M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Guangzhou Innogen Pharmaceutl Grp Co's EBIT against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.